Clinical and Experimental Medicine

, Volume 5, Issue 4, pp 135–140

Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin

  • A. Ephrem
  • N. Misra
  • G. Hassan
  • S. Dasgupta
  • S. Delignat
  • J.-P. Duong Van Huyen
  • S. Chamat
  • F. Prost
  • S. Lacroix-Desmazes
  • S. V. Kavery
  • M. D Kazatchkine
REVIEW

DOI: 10.1007/s10238-005-0079-y

Cite this article as:
Ephrem, A., Misra, N., Hassan, G. et al. Clin. Exper.Med. (2005) 5: 135. doi:10.1007/s10238-005-0079-y

Abstract

Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. Its use has also been reported in a large number of other autoimmune and systemic inflammatory conditions. In this review, we discuss the mechanisms by which IVIg exerts immunomodulatory effects in immune pathologies.

Key words

Intravenous immunoglobulin Autoimmune disorders Inflammatory diseases Mechanisms 

Copyright information

© Springer-Verlag Italia 2005

Authors and Affiliations

  • A. Ephrem
    • 1
  • N. Misra
    • 1
  • G. Hassan
    • 1
  • S. Dasgupta
    • 1
  • S. Delignat
    • 1
  • J.-P. Duong Van Huyen
    • 1
  • S. Chamat
    • 1
  • F. Prost
    • 1
  • S. Lacroix-Desmazes
    • 1
  • S. V. Kavery
    • 1
  • M. D Kazatchkine
    • 1
  1. 1.INSERM U430 and Université Pierre et Marie Curie (UPMC-Paris 6), Hôpital BroussaisParisFrance

Personalised recommendations